Sign In
Buy JNJ
$231.29
+2.90 (+1.27%)
At Close: Jun 22, 2026
Johnson & Johnson's Spravato sales growth signals upside for psychedelics peers like AtaiBeckley
03:22pm, Tuesday, 14'th Apr 2026
Johnson & Johnson (NYSE:JNJ)'s Spravato is reinforcing investor interest in the broader psychedelics sector as it reported another quarter of strong sales growth, with Jefferies analysts pointing to i
Johnson & Johnson: A 20% Gain Looks Easy After Q1 Earnings Results
02:10pm, Tuesday, 14'th Apr 2026
Johnson & Johnson's NYSE: JNJ price action entered consolidation in early March. While it may continue moving sideways or even pull back further, those moves are unlikely, given a convergence of facto
Johnson & Johnson Q2 Earnings Review: Why You Should Be Buying The Stock Today
01:47pm, Tuesday, 14'th Apr 2026
Johnson & Johnson delivered a robust Q1, with revenues up nearly 10% YoY to $24.1bn and a raised full-year 2026 sales guidance above $100bn. JNJ's diversified portfolio—driven by double-digit growth
J&J Beats Q1 Earnings & Sales Estimates, Raises 2026 Outlook
01:30pm, Tuesday, 14'th Apr 2026
JNJ tops Q1 earnings and sales estimates, lifts 2026 outlook as strong oncology and MedTech growth offset steep Stelara decline.
Johnson and Johnson Raises Dividend for 64th Consecutive Year
12:55pm, Tuesday, 14'th Apr 2026
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) declared its 64th consecutive annual dividend increase on April 14, 2026, lifting its quarterly payout from $1.30 per share to $1.34 per share, a 3%
Johnson & Johnson (JNJ) Shows Steady Growth Amid Investment Pressures
12:14pm, Tuesday, 14'th Apr 2026
Johnson and Johnson (JNJ) has shown a muted market response after releasing its Q1 2026 earnings report. The company surpassed consensus estimates and slightly in
Johnson & Johnson’s Spravato sales growth signals upside for psychedelics peers like AtaiBeckley
11:18am, Tuesday, 14'th Apr 2026
Johnson & Johnson (NYSE:JNJ)’s Spravato is reinforcing investor interest in the broader psychedelics sector as it reported another quarter of strong sales...
Johnson & Johnson CFO on the company's robotic surgical system
10:51am, Tuesday, 14'th Apr 2026
Johnson & Johnson CFO Joseph Wolk discusses the company's latest FDA application for its OTTAVA robotic surgical system.
Johnson & Johnson (JNJ) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
10:31am, Tuesday, 14'th Apr 2026
Although the revenue and EPS for Johnson & Johnson (JNJ) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wal
Tuesday's Morning Movers: ORCL & BE Extend Partnership, KMX & JNJ Earnings
10:30am, Tuesday, 14'th Apr 2026
Oracle's (ORCL) rebound rally continues after extending a partnership with Bloom energy (BE). Diane King Hall explains why the headline offers a bullish catalyst for both companies.
Johnson & Johnson beats quarterly revenue estimates, maintains full-year outlook
10:25am, Tuesday, 14'th Apr 2026
Johnson & Johnson (NYSE:JNJ) reported first-quarter results on Tuesday that beat Wall Street expectations for revenue, driven by solid growth across its pharmaceutical and medical technology businesse
Dow Jones' J&J Slips Despite Beating First-Quarter Calls, Hiking Guidance
09:06am, Tuesday, 14'th Apr 2026
Johnson & Johnson stock fell early Tuesday despite better-than-expected first-quarter sales and earnings, and a guidance boost.
Stocks Eye More Gains Amid Peace Deal Hopes
08:58am, Tuesday, 14'th Apr 2026
Dow futures are flat this morning, but the S&P 500 and Nasdaq-100 are headed for gains amid peace deal hopes
Johnson & Johnson (JNJ) Surpasses Q1 Earnings and Revenue Estimates
08:30am, Tuesday, 14'th Apr 2026
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.7 per share, beating the Zacks Consensus Estimate of $2.67 per share. This compares to earnings of $2.77 per share a year ago.
On April 14, 2026, Johnson and Johnson (JNJ) released its 8-K filing detailing first-quarter 2026 results. Reported sales rose 9.9% year over year to $24.06 billi
